The use of dental implants is considered a predictable therapeutic option for the rehabilitation of partially or fully edentulous patients providing long-term function and esthetics (Jung et al. 2012; Pjetursson et al. 2012b; Chappuis et al. 2013) . The indication spectrum includes various prosthetic reconstructions of either fixed or removable nature. As their development in the early 1970s (Branemark et al. 1969 (Branemark et al. , 1971 Adell et al. 1970; Schroeder et al. 1976 Schroeder et al. , 1978 , the promising long-term data of dental implants (Branemark et al. 1977; Adell et al. 1981; Buser et al. 1997; Merickse-Stern et al. 2001) resulted in an increasing number of implant systems with different designs and surfaces on the market. In general, two main types of dental implant designs are distinguished:
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To cite this article: Gamper FB, Benic GI, Sanz-Martin I, Asgeirsson AG, H€ ammerle CHF, Thoma DS. Randomized controlled clinical trial comparing one-piece and two-piece dental implants supporting fixed and removable dental prostheses: 4-to 6-year observations. Clin. Oral Impl. Res. 28, 2017, 1553-1559 doi: 10.1111/clr.13025 one-piece and two-piece implants. One-piece implants are characterized by a rough body for intraosseous placement and a machined collar, the latter part emerging through the soft tissues (Scacchi 2000; Scacchi et al. 2000) . Two-piece dental implants were originally designed for submerged healing. Submerging appears to reduce initial bone resorption after implant placement (Ericsson et al. 1994 (Ericsson et al. , 1996 . A second surgical intervention (abutment connection) (Branemark et al. 1969 (Branemark et al. , 1977 then becomes necessary, however, to connect the prosthesis to the implant. Following this second-stage procedure, remodeling of the marginal bone takes place (Esposito et al. 1993; Tarnow et al. 2003; Belser et al. 1998) . Both types of implants have been used for years and longterm data demonstrate high survival rates (Derks et al. 2015) . Apart from survival rates, the number of complications on the implant and the prosthetic level is of high interest for both clinicians and patients alike. In systematic reviews (Jung et al. 2012; Pjetursson et al. 2012b ), complication rates have been shown in a range of 3.5-8.8% (technical), 2.6-8.5% (biological), and 3.6-13-6% (esthetic). Today, it is unknown whether the general design differences between one-and twopiece dental implants affect the long-term rates of technical, biological, and esthetic complications. There are few clinical studies comparing different implant systems, such as one-versus two-piece implants (Astrand et al. 1999; Moberg et al. 2001; Pinholt 2003; Meijer et al. 2004; Thoma et al. 2014) . Moreover, the literature is scarce in terms of randomized controlled clinical trials (RCTs) comparing different implant systems (Esposito et al. 2005) . In a systematic review, only four RCTs fulfilled the inclusion criteria and reported on a total of 204 patients. It was concluded that there is no strong evidence supporting the superiority of one implant system over others. It is important to note that this review was based on a few RCTs, evaluating few implant systems in few patients. Hence, a clear need was stated for more long-term studies comparing different implant systems.
The aim of the present clinical trial was, therefore, to test whether or not a one-(S1) and a two-piece (S2) dental implant system render the same biological, technical, and esthetic outcomes regarding implants and implant-supported reconstructions over an observation period of 4 to 6 years.
Materials and methods
The study was designed as a randomized controlled clinical trial and approved by the local ethical committee as a long-term non-interventional study (KEK-ZH-Nr 2014-0201). The specific protocol and inclusion criteria were described in a previous publication (Thoma et al. 2014) . In brief, sixty partially or fully edentulous patients (S1: 13 males and 17 females; S2: 10 males and 20 females) in need of implant therapy were consecutively included and randomly allocated to one of the two groups using a computer-generated randomization list. Exclusion criteria were general contraindications for implant therapy (systemic or local diseases) and patients not fulfilling the inclusion criteria (medically healthy and older than 18 years). Patients signed an informed consent and were, according to a computer-generated list, randomly assigned to receive one-piece (Straumann tissue-level implants, Institut Straumann, Basel, Switzerland; S1) or two-piece dental implants (Br anemark MkIII or MkIV, Nobel Biocare, Zurich, Switzerland; S2). All implant surgeries were performed according to the manufacturer's guidelines. S1 implants were placed with the transition between the rough and smooth surface at the bone crest and S2 implants with the flat top at the bone crest. Some implants were placed with increased sink depth below the bone crest if necessary for prosthetic reasons. The majority of the implants in both groups received a bone augmentation procedure (Details in Table 1 ). Subsequently, implants were subjected to a submerged or transmucosal healing irrespective of the implant design (one-or twopiece implant). The type of healing was dependent on the location and whether or not bone augmentation procedures were performed.
Baseline and follow-up examinations
The insertion of the final reconstruction (between 2004 and 2008) was chosen as baseline, and patients were subsequently enrolled in an individually designed maintenance program with periodic visits to the dental hygienist. The dental hygiene sessions were performed either at the Clinic of Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Switzerland, or in private practices. At baseline, the mean age for patients with S1 was 47.5 years (standard deviation [SD] AE 15) and 55.8 years (AE14) for the S2 group. All 151 implants (S1: 65; S2: 86) were inserted between 2002 and 2005. A total of 14 patients reported smoking habits: nine patients in the S1 group (2 patient <5 cigs/day; 7 patients >5 cigs/day) and five patients in the S2 group (1 patient <5 cigs/day; 4 patients >5 cigs/day). Only three patients (1 in S1, 2 in S2) reported habits of bruxism. The differences with regard to smoking and bruxism were not significant between the two groups (Thoma et al. 2014) . Implant length and implant diameter were recorded, and no significant differences were found between the two groups (P = 0.157, P = 0.144 respectively).
All sixty patients, however, were recalled for the follow-up examinations at one year and again at 4 to 6 years (FU-5) following the insertion of the final reconstruction at the Clinic of Fixed and Removable Prosthodontics and Dental Material Science, University of Zurich, Switzerland. The numbers in parentheses display the number of implants. S1 = one-piece (Straumann tissue-level implants, Institut Straumann, Basel, Switzerland) and S2 = two-piece dental implants (Br anemark MkIII or MkIV, Nobel Biocare, Zurich, Switzerland). GBR, guided bone regeneration; some implants received both primary and simultaneous augmentation procedures; SC, single crowns; 2FDP, 2-unit cantilevered FDP; FDP, splinted single crowns and implant-borne multiunit reconstructions without cantilever; cFDP, cantilevered splinted single crowns and implant-borne multiunit reconstructions; TISPs, tooth-implant-supported prostheses; ISRDs, implant-supported removable dentures.
Outcome measures
The following biological, technical, and esthetic parameters were assessed at baseline, one year, and at 4 to 6 years:
Biological outcome measures
A full-mouth periodontal status was recorded in each patient. This included probing pocket depth (PPD) (Ramfjord 1974) , clinical attachment level (CAL), plaque control record (PCR) (O'Leary et al. 1972) , and bleeding on probing (BOP) (Ainamo & Bay 1975) . All measurements were recorded at six sites per tooth and implant using a UNC-15 periodontal probe (Hu-Friedy, Chicago, IL, USA). In addition, the width of the keratinized mucosa was measured at the buccal aspect of all implants. Intraoral radiographs were taken using a paralleling technique with standardized rim-holders and analog films (Kodak Ektaspeed Plus, Eastman Kodak Co., Rochester, NY, USA). After digital scanning of the X-rays, X-rays taken at the different time-points of assessment were compared and changes of the marginal bone level over time were calculated using an open-source software (ImageJ, National Institutes of Health, Bethesda, Maryland USA) For calibration purposes, the distance between two implant threads and the determination of the exact magnification of the images was used. The reference point of the two-piece implant (S2) was the most coronal point of the flat top of the implant. At the one-piece implant (S1), the implant shoulder served as reference point for the measurements. The marginal bone level was assessed at the mesial and distal implant surfaces by measuring the distance from the reference point of the implant to the first bone-to-implant contact (fBIC). For S1 implants, the expected bone level was at the transition between the rough and smooth surface. Therefore, 1.8 mm (height of smooth collar) was deducted from all fBIC values. For S2 implants, the bone level was expected at the flat top. No correction of fBIC values was therefore performed for S2 implants (Astrand et al. 2002 ).
In addition, the incidence of biological complications was documented in the patient records and at the follow-up examinations. This included the following: peri-implant mucositis (clinical signs of inflammation without crestal bone loss, probing pocket depth ≥ 5 mm and bleeding on probing at >50% of the sites at a given implant), and peri-implantitis (mucositis in conjunction with crestal bone loss ≥2 mm; Mombelli & Lang 1994).
Technical outcome measures
All technical complications such as implant fracture, fracture or loosening of prosthetic screws, fracture or loosening of abutments, fracture of framework and/or veneering ceramic (minor, major), loss of retention for cemented restorations or loosening of screw access hole restorations were continuously documented in the patient records and at the follow-up examinations.
Esthetic and further outcome measures
The following additional parameters were recorded visibility of the crown margin (yes or no), shimmering of the implant through the mucosa (yes or no), the level of the periimplant margo mucosae compared to the contralateral tooth or implant site (similar, positive/negative (margo of implant site more coronal/apical) than contralateral site), and the modified papilla index (Jemt 1997) .
Moreover, biological and technical complications as well as survival rates of implants and reconstructions were calculated at FU-5. Survival was defined as remaining in situ and in function regardless of therapeutical interventions during the observation period.
Statistical analysis
All data were recorded in Microsoft Excel spreadsheets (Microsoft Corporation, Redmond, WA, USA). For the descriptive part of the paper median, quartiles, mean, and standard deviation were computed on implantbased data. Due to the fact that the generated data were asymmetric and showed statistical outliers, the authors decided to report medians with quartiles in the text. Because of the same reasons, nonparametric mixed models were used for the patient-level analysis. The rates were compared with Fisher's exact test, and the corresponding 95% confidence intervals were derived using the Binomial distribution. Data were analyzed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA).
Results

Demographic data
Originally, 60 patients were treated with 151 dental implants. The prosthetic reconstructions were removable (17 of the implants), screw-retained (103 of the implants), or cemented (31 of the implants). In total, a number of 93 fixed and six removable prostheses were placed. A detailed overview of the prosthetic reconstructions is reported in Table 1 . The overall mean implant length was 11.2 mm (S1: 11.5 AE 1.7 mm; S2: 10.7 AE 1.6 mm), whereas the mean implant diameter was 4.1 mm (S1: 4.0 AE 0.3 mm, S2: 4.2 AE 0.0 mm). Details related to the distribution of the implants in the oral cavity are listed in a previous publication (Thoma et al. 2014) .
The median follow-up time was 5.0 years (Q1: 4.7; Q3: 5.2; range 4.2-6.4 years) and the mean age of the patients 52.7 years (AE15) for group S1 and 60.8 years (AE14) for group S2. One male patient and three female patients with a total number of six implants (all in group S1) were recorded as dropouts (6.7%). The reasons for the dropout were due to a cancer-induced resection of the whole upper jaw (one patient; two implants; cementretained cantilevered splinted single crowns; S1), inability to travel to the study clinic due to patient's relocation (one patient; two implants; cement-retained splinted single crowns; S1), or failure to contact the patients (two patients; two implants; screw-retained single crowns; S1) ( Table 1) .
Survival rates
During the observation period, a total number of three implants were lost. All of them had to be explanted because of progressive bone-loss and peri-implant disease, two SCs in group S1 (in two different patients), one-two-unit FDP on two implants (2FDP) in group S2. Overall, the cumulative implant-based survival rate was therefore 97.9% (142 of 145 implants) at FU-5. Splitting the two groups, the survival rates changed to 96.6% (57/59 implants) for S1 and 98.9% (85/86 implants) for S2.
On the patient-level, the overall cumulative implant survival rate was 94.6% (53/56) at FU-5. Calculated for group S1 (24/26), the survival rate was 92.3% (95% CI [77%, 99%]) and 96.7% (95% CI [84%, 99.9%]) for group S2 (29/30). The survival rates of S1 and S2 did not differ significantly (P = 0.592).
Radiographic outcomes
On the implant level, the median marginal bone level at baseline was 0.51 mm (quartiles [Q]: 0.14;0.96) for S1 and 1.02 mm (Q: 0.82;1.23) for S2. At FU-5, the median marginal bone level was 0.49 mm (Q: 0.16;0.93) for S1 and 1.35 mm (Q: 1.12;1.63) for S2 (Table 2A) . The intergroup patient-based analysis (S1 vs. S2) revealed no significant differences in terms of marginal bone levels at baseline (P = 0.0722) and significant differences in favor of group S1 at FU-5 (P = 0.0014) ( Table 2B ). The intragroup patient-based analysis revealed statistically significant differences of the marginal bone-level changes between baseline and FU-5 for group S2 (P = 0.0002), but not for group S1 (P = 1.00) ( Table 2C ). The intergroup comparison for changes between baseline and FU-5 was statistically significantly different between S1 and S2 (P < 0.001).
Biological outcomes
Except for peri-implantitis, all parameters measured (PPD, PCR, BOP, and the width of the keratinized mucosa) were similar for both groups and at both time-points (Table 3) . Over the observation period, the number of implants diagnosed with peri-implant mucositis was 3/57 (5.3%) in two patients for S1 and 9/85 (10.6%) in three patients for S2. Six of nine implants diagnosed with periimplant mucositis in group S2 were in the same patient, treated with a bar-retained hybrid prosthesis. On the patient-level, the rate for peri-implant mucositis was 7.7% (95% CI [1%, 23%]) for group S1 (2/26) and 10.0% (95% CI [3%, 25%]) for group S2 (3/ 30) up to FU-5. These rates between the two groups did not differ significantly (P = 1.00).
The number of implants affected by periimplant disease was 4/57 (7.0%) for S1 and 7/ 86 (8.1%) for S2. In group S1, only two patients were affected (one patient, two implants; one patient, two implants). In group S2, seven implants in four patients were diagnosed with peri-implantitis (one patient, one implant; one patient, one implant; one patient, two implants; one patient, three implants). These implants showing progressive bone loss and were treated according to a standard protocols both non-surgically and surgically. On the level of the patient, the cumulative rate for peri-implantitis was 10.7% (6/56), 7.7% (95% CI [1%, 23%]) for group S1 (2/26) and 13.3% (95% CI [5%, 29%]) for group S2 (4/30) (P = 0.675) at FU-5.
The patient-based analysis revealed a total biological complication rate of 19.6% (11/56), resulting in 15.4% (95% CI [5%, 33%]) for S1 (4/26) and in 23.3% (95% CI [10%, 41%]) for S2 (7/30) (P = 0.517).
Technical outcomes
During a median observation period of 5 years, 23 of 145 implants demonstrated a total number of 30 technical complications.
Twenty-two of the 27 affected implants were in group S1 showing 83.3% (25/30) of all technical complications in the present study. This included for group S1: eight matrices having been renewed (2/8 in the same patient/same implant; 5/8 in the same patient on five different implants; 1/8 in one patient, one implant), 10 screw loosenings (1/ 10 in one patient, one implant; 2/10 in one patient, one implant; 3/10 in one patient, three implants; 4/10 in one patient, four implants), four minor chippings (2/4 in one patient, two implants; 2/4 in one patient, two implants), and three times a loss of the screw access hole restorations (in one patient, three implants). The patient-based analysis revealed a total technical complication rate of 34.6% [95% CI (17.2%, 55.7%]) for S1 (9/26). In group S2, five implants showed five technical complications, which resulted in 19.2% (5/26) of all reported complications. This included the following: three minor chippings (2/3 in one patient, two implants; 1/3 in one patient, one implant), one major chipping (one patient, one Table 2 . Marginal bone level (MBL) at baseline and at FU-5 and marginal bone-level alterations between baseline and FU-5. (A) Implant-level analysis of MBL at baseline and at FU-5 with means, SD's, medians, and quartiles. (B) Patient-level analysis of intergroup comparisons between S1 and S2 at baseline and at FU-5; P-values between the groups for each time-point. (C) Patient-level analysis of MBL changes over time with means, standard deviations (SD), and P-values within the groups nBL = number of patients at baseline; n5y = number of patients at FU-5; P-values within the groups over time. nS1 = number of patients in group S1; nS2 = number of patients in group S2. S1 = one-piece (Straumann tissue level implants, Institut Straumann, Basel, Switzerland) and S2 = two-piece dental implants (Br anemark MkIII or MkIV, Nobel Biocare, Zurich, Switzerland). implant), and one loss of the screw access hole restoration (one patient, one implant).
The patient-based analysis revealed a total technical complication rate of 13.3% (95% CI [5%, 29%]) for S2 (4/30). The patient-based rates of the two groups were not significantly different (P = 0.349).
In both groups, no implant fractures, fractures of the prosthetic screws, fractures of the abutments, or fractures of the frameworks occurred. In group S1, two reconstructions had to be renewed. One due to a major chipping, one due to the loss of the abutment tooth wearing a tooth-implant-supported prostheses.
These findings resulted in a cumulative implant-based survival rate of the prosthetic reconstructions of 96.6% (140 of 145 implants), divided into 93.2% (55 of 59 implants) for S1 and 98.9% (85 of 86 implants) for S2.
Based on the patient level, the cumulative survival rate of the prosthesis was 96.4% (54/ 56). About 92.3% (95% CI [77%, 99%]) of the reconstructions survived in group S1 (24/26) and 100% (95% CI [90%, 100%]) survived in group S2 (30/30) (P = 0.211).
Esthetic and further outcome measures
In group S1, a modified papilla index with values ≤2 was found in 32 implants at 1 year and in 24 implants at FU-5 (S2: 37 and 59 implants, respectively). The peri-implant mucosal margin was located more apical compared to the contralateral tooth site in 22 implants at 1 year and in 30 implants at FU-5 (group S1). In group S2, the respective number of implants was 22 at 1 year and 42 at FU-5. A shimmering of the implant through the mucosa was observed at 6 and 12 implant sites (at 1 year and at FU-5) in group S1. The respective number of implants in group S2 was 12 (1 year) and 28 (FU-5). All details are displayed in Table 4 .
Discussion
The present RCT comparing two types of implant systems demonstrated: i) high implant and prosthetic survival rates without significant differences between the two implant systems up to FU-5; ii) significantly higher marginal bone levels (MBL) at FU-5 and non-significant changes of MBL from baseline to FU-5 for the one-piece dental implant system; iii) significantly lower marginal bone levels (MBL) and significant changes of MBL from baseline to FU-5 for the two-piece implant system; and iv) a lower rate of biological, but a higher rate of technical complications for the one-piece compared to the two-piece implant system.
Within the present study, a high cumulative implant survival rate of 97.9% was recorded. This survival rate compares well to the 97.3% implant survival rate at a 3-year follow-up reported in another study comparing the same two implant systems (Astrand et al. 2004) . In that randomized split-mouth study in the maxilla, two-piece implants (Br anemark Implants, Nobel Biocare) were placed on one side and one-piece implants (Straumann Implants, Institut Straumann) on the contralateral side of the residual dentition. The data are further in line with two previously published systematic reviews reporting five year survival rates of 95.6% for implants supporting FDPs (Pjetursson et al. 2012b) and 97.2% for implants supporting SCs (Jung et al. 2012) .
In addition, a high prosthetic survival rate of 96.6% was found. Two previously published prospective studies evaluating the same two-piece dental implants and the respective FDPs showed estimated survival rates of the reconstructions of 96.3% (Ortorp & Jemt 2008 ) and 97.0% (Andersson et al. 2003) after observation periods of 5 years. For the one-piece dental implant system, two prospective clinical trials reported even slightly increased estimated prosthetic survival rates of 97.5% (Bragger et al. 2001 ) and 98.7% (Behneke et al. 2000) after observation periods of 5 years. Based on the two systematic reviews (Jung et al. 2008b; Pjetursson et al. 2012b ), meta-analyses revealed a survival rate of implant-supported SCs of 94.5% and of 95.4% for implant-borne FDPs after 5 years in function. In summary, both, implant and prosthetic survival rates in the present study are in agreement with previously published prospective studies and systematic reviews.
The marginal bone levels and bone-level changes represent an indicator of osseointegration and biological success of the implant. A bone loss of 1.5 mm in the first year and 0.2 mm in every following year has previously been considered acceptable (Albrektsson et al. 1986 ). Thus, a bone loss of 2.3 mm (1.5 + 4 9 0.2 mm) would be considered a success at 5 years of loading. With a median bone level of 0.51 mm at baseline and 0.49 mm at FU-5 for group S1 and 1.02 mm at baseline and 1.35 mm at FU-5 for group S2, the results in both groups demonstrated clinically superior results than the hitherto suggested success criteria (Albrektsson et al. 1986 ). In the previously mentioned comparative study (Astrand et al. 2004 ) applying the same two implant systems, a mean marginal bone level for the one-piece implant of 1.4 mm at baseline and 1.3 mm at the 3-year follow-up was reported. For the two-piece implant system, the marginal bone level was located 1.8 mm from the reference point at both time-points. The differences observed between the present and the above-mentioned study might be due to the reference points chosen. Both studies, however, have in common that marginal bone levels demonstrate only minimal changes over time for the one-piece implant system. In the present study, the two-piece implants showed more marginal bone loss over time. It has previously been reported at the one-year follow-up of the same patient cohort (Thoma et al. 2014 ) that this observation might mainly be associated with twopiece implants having been placed deeper with respect to the bone crest than the onepiece implants. Similar observations, with more marginal bone loss due to greater vertical sink depth, were made in preclinical and clinical studies (Hammerle et al. 1996; Jung et al. 2008a) .
In terms of further biological complications such as peri-implant mucositis or periimplantitis, the one-piece implant system demonstrated less biological complications than the two-piece implant system. Even though no statistically significant difference was found, group S1 showed higher percentages of both peri-implant mucositis and periimplantitis than group S2. These data are in contrast to the findings of a previous splitmouth-study (Astrand et al. 2004) . In that study, 9.1% (7/77) of the one-piece dental implants and none of the two-piece dental implants were affected by peri-implant disease. One has to bear in mind, however, that the scientific evidence is inconsistent regarding less or more biological complications for a specific implant system. Moreover, there is a lack of standardization in terms of assessing and classifying peri-implant diseases. Peri-implantitis was defined as follows in the present study: probing pocket depth (PPD) ≥5 mm, bleeding on probing/suppuration and bone loss of ≥2 mm (Mombelli & Lang 1994) . Peri-implant mucositis was defined as probing pocket depth (PPD) ≥5 mm, bleeding on probing/suppuration without bone loss (Renvert et al. 2008 ). The patient-based periimplantitis rate found in a study with 70 patients, 165 one-piece implants and a mean follow-up rate of 7.9 years, was 17.1% (Pjetursson et al. 2012a) . In one of the most recent, large-scale clinical analysis, 588 patients having diverse implant systems were investigated 9 years after implant therapy. The reported patient-based prevalence of moderate/severe peri-implantitis was 14.5%. In terms of the odds ratios for moderate/severe peri-implantitis, significantly higher incidences for patients provided with two-piece implants were observed compared to patients provided with one-piece dental implants (Derks et al. 2016 ).
The two implant systems differed in the extent of technical complications encountered for the fixed and removable reconstructions. Eighty-three percent of all technical complications were found in group S1, mainly including renewal of the matrices (removable prostheses) and screw loosening of the fixed reconstructions. Taking into account the limited number of removable prostheses (n = 5) and the fact that all complications related to those types of reconstructions affected only three different patients (and 45.5% of the complications even the same implant), these findings have to be interpreted with caution. A comparative randomized study including the same two implant systems for the treatment of mandibular edentulism with full-arch bridges revealed more need for adjustments in the one-piece implant group during the three-year follow-up period (Moberg et al. 2001) . This is in line with the outcomes of the present study. Another prospective randomized study comparing one-and two-piece dental implants to support mandibular overdentures revealed no significant differences in the prosthetic aftercare over a follow-up period of 5 and even over 10 years (Meijer et al. 2004 (Meijer et al. , 2009 ). The minimal number of removable implant-supported dentures, however, in the present study does not allow drawing any conclusions. The frequency of screw loosening has been reported to be 8.8% for single crowns (Jung et al. 2012 ) and 5.3% for multiunit reconstructions (Pjetursson et al. 2012b) . One might speculate that the relatively high rate of screw loosenings (15.3% for group S1 and 0.0% for group S2 resulting in an overall rate of 6.2%) was associated with the use of an intermediate abutment (for the one-piece implant system). In all fixed reconstructions, this intermediate abutment was connected to the implant and the final reconstruction then screwed on top with a much lower torque. A retrospective analysis of the same one-piece implant system and intermediate abutments used for single-tooth components found an 8.7% incidence rate of occlusal screw loosening at 6 months (Levine et al. 1997) . Interestingly, the same research group reported a massive increase of occlusal screw loosening up to 22.2% after 2 or more years in function (Levine et al. 1999) . In daily practice, clinicians normally have to choose one implant system, which they will then use for all indications, patients and sites. The outcomes of the present study reflect that both implant systems can be used for fixed and removable reconstructions, for a variety of indications, in partially and fully edentulous patients, for single crowns and multiunit reconstructions. Survival and complications rates were well within the magnitude of other clinical trials using often more strict inclusion criteria and highly limited indications. From a strictly scientific point of view, the information derived from the present RCT comparing two implant systems must, however, be interpreted with caution due to the asymmetric distribution of the implants and the heterogeneity of the reconstructions.
Conclusions
Both implant systems reveal high survival rates on the implant and prosthetic level over an observation period of 4-6 years without significant differences between the two groups. Apart from marginal bone-level changes (in favor of the one-piece implant system), biological, and technical outcomes did not reveal significant differences.
